drugset
drugset / Trial / NCT05951946

A Study to Evaluate Drug-drug Interactions and Safety Between "BR3006-1", "BR3006-2", and "BR3006-3" in Healthy Volunteers

NCT05951946 ↗

Phase 1 Completed 37 enrolled Boryung Pharmaceutical Co., Ltd
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this clinical trial is to evaluate drug-drug interactions and safety between "BR3006-1", "BR3006-2", and "BR3006-3" in healthy volunteers

Timeline

Start
2023-07-22
Primary completion
2023-09-11
Completion
2023-09-11

Drugs

EvaluationDrugModalityDoseRoute
Subject BR3006-1 Unknown — Oral
Subject BR3006-2 Unknown — Oral
Subject BR3006-3 Unknown — Oral

Indications

diabetes mellitus